UNCERTAINTIES
What is the best treatment to reduce the need for caesarean section in nulliparous women at term with delayed first stage of labour? Sara Labour is commonly divided into three stages. The duration of the first and second stages of labour vary, dependent on parity. Figure 1⇓ depicts the stages of labour and expected duration as defined by the National Institute for Health and Care Excellence (NICE).
1 Nulliparous women tend to have a longer labour than multiparous women. Delay can result from poor uterine contractions or the relationship between size, presentation, and position of the fetus and the maternal pelvis that obstructs vaginal delivery. Uterine contractile dysfunction affects between 11% and 30% of nulliparous women [2] [3] [4] and is the focus of this paper.
Delayed labour-There is some variation worldwide in the definition of delayed labour (table 1⇓) . The World Health Organization considers delay as a rate of cervical dilation of less than 0.5-1 cm in four hours once labour is established, whereas NICE recommends waiting a further two hours with cervical dilation of less than 1 cm before delay is confirmed. Prolonged labour is associated with higher rates of chorioamnionitis 9 with risk of neonatal sepsis and of unplanned caesarean section with associated risks of infection and bleeding.
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Oxytocin-Treatment for a confirmed delay in labour is with intravenous oxytocin 1 5 to re-establish effective uterine contractions. The dose is titrated against the strength and frequency of uterine contractions by means of a variable rate infusion pump and taking into account fetal wellbeing through electronic fetal heart monitoring. Adverse effects include uterine tachysystole and uterine hyperstimulation (see box 1 for definitions), which are associated with hypoxic ischaemic encephalopathy and neonatal death. Mother and baby therefore need to be intensively monitored during treatment with oxytocin. Injudicious use of oxytocin and inappropriate management during labour have resulted in cases of fetal hypoxia and resultant controversy around its use. 13 There is no consensus on the optimal dose regimen of oxytocin for delay in the first stage of labour in nulliparous women at term (37-42 weeks' gestation) to reduce unplanned caesarean section and increase vaginal birth with minimal adverse events. Recommendations are lacking apart from in the UK (table 1⇓) , and the regimens used vary widely even within the same country, 14 despite calls for a standardised regimen.
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What is the evidence of uncertainty?
Limited evidence from randomised trials suggests that use of oxytocin at a low dose shortens labour but does not affect whether the baby is born normally, by means of instruments (forceps or ventouse), or by caesarean section. 1 16 With respect to the effectiveness of high dose regimens of oxytocin, the Cochrane review 17 published in 2013 (including 644 women, three randomised controlled trials, and one quasi-randomised trial) compared high dose oxytocin regimens with low dose regimens in women delayed in normal labour. Because of variation in the dose regimens in the trials, the authors defined high dose oxytocin as starting dose and increments >4 mU/minute and low dose oxytocin as starting dose 1-4 mU/minute and increments of 1-2 mU/minute. High dose regimens were associated with a decrease in the rate of caesarean section (risk ratio 0.62; 95% confidence interval 0.44 
PRACTICE
What you need to know
• Prolonged labour is associated with adverse outcomes for mother and fetus, and intravenous oxytocin is the mainstay of treatment
• There is uncertainty as to the optimal regimen of oxytocin to decrease the chances of caesarean section with minimal adverse effects, and there is some evidence that high dose regimens may be effective
• Administer oxytocin in hospital where the mother and baby can be closely monitored
Box 1: Definitions of terms used
Nulliparous-Woman who has not given birth before
Uterine tachysystole-Increased uterine contractions; >5 uterine contractions in 10 minutes for 20 minutes
Uterine hyperstimulation-Tachysystole with abnormal features of the fetal heart rate suggestive of hypoxia to 0.86), although there was some doubt about this estimate because of heterogeneity of treatment effect estimates (risk ratio 0.67; 0.38 to 1.18) under alternative model assumptions. The only trial reporting length of labour 17 included only 40 women and reported a reduction with high dose of oxytocin (mean difference −3.50 hours; 95% CI −6.38 to −0.62). Two of the trials included both nulliparous and multiparous women, which limits interpretation of findings. No differences were noted in other maternal and neonatal outcomes or adverse effects.
There is uncertainty as to women's views of the use of oxytocin, with most trials focusing on clinical outcomes. 18 Limited qualitative evidence from interviews with women who experienced prolonged labour suggests that intervention is acceptable to women 19 and that, in case of a delay, women preferred to defer decision making to professionals. 
Is ongoing research likely to provide relevant evidence?
No further trials have been reported since publication of the Cochrane review, but several are ongoing. We searched the WHO International Clinical Trials Registry Platform and Clinicaltrials.gov in January 2017 and identified three ongoing trials comparing low dose and high dose oxytocin for delay in the first stage of labour in nulliparous women (see box 2 for details).
These studies are likely to provide evidence on effectiveness and safety of a high dose oxytocin regimen in delayed labour to reduce duration of labour and improve chances of spontaneous vaginal birth. The trials are taking place in America, Sweden, and the UK. 
What should we do in light of the uncertainty?
Nulliparous women and women with a higher body mass index have higher risk for slow progress in labour. 21 At the antenatal visit close to term, discuss with the woman and her partner the expected duration and stages of labour and the possibility of prolonged labour. Emphasise the importance of remaining mobile and hydrated during labour. Explain that, if labour progresses more slowly than expected, there is an increased chance of infection and of requiring a caesarean section. At the start of labour, inform the woman that progress of labour and wellbeing of the fetus will be monitored throughout. Regular vaginal examinations will be done to assess cervical dilatation. As there is variation in the definitions of delay in labour, rely on the relevant guidelines to make a diagnosis (table 1⇓) .
Women with prolonged labour can opt to wait and see how labour progresses without augmentation by oxytocin. Intravenous oxytocin may be offered to strengthen uterine contractions and accelerate progress, but there is only limited evidence that this will increase the likelihood of spontaneous delivery.
In case of a delay, offer pain relief and intravenous oxytocin until the woman gives birth. Further evidence is required before offering high dose oxytocin outside of a research setting. Oxytocin should be given only where close monitoring of the mother and fetus is possible and where adequate pain relief can be given. If the woman is in labour outside an obstetric unit, timely referral to a hospital for assessment and appropriate intervention is recommended.
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Contributors: SK drafted the paper which was seen and commented on by all members of the HOLDS Collaborative Group. Setting and population-Three hospitals in southwest Sweden; 1376 nulliparous women at term in spontaneous active labour (regular painful contractions, effaced cervix, dilated > 3-4 cm) whose progress is delayed defined with a 3 hour partogram action line
High dose regimen-Initial infusion 6.6 mU/minute increasing every 20 minutes by 6.6 mU to maximum of 59.4 mU/minute
Low dose regimen-Initial infusion 3.3 mU/minute increasing every 20 minutes by 3.3 mU to maximum of 29.7 mU/minute (this is the recommended standard dose in Sweden)
Primary outcome-Caesarean section
NCT02487797
Randomized double blind clinical trial comparing oxytocin low dose and high dose regimens for labour augmentation. 
Box 3: Recommendations for further research
Population-Nulliparous women with a singleton pregnancy at term with delayed progress in the first stage of spontaneous labour
Intervention-High dose regimens of oxytocin

Comparison-Low dose regimens of oxytocin
Outcome-Mode of birth (vaginal birth or caesarean section), safety, harms, duration of labour, women's acceptability and satisfaction
Sources and selection criteria
We searched the websites of English speaking Colleges of Obstetricians and Gynaecologists internationally for definitions of normal and delayed labour and treatment. We also searched WHO Guidelines and in the UK NICE guidelines (detailed in table 1⇓).
For evidence of effectiveness of oxytocin, we searched the Cochrane Database of Systematic Reviews and Clinical Evidence in January 2017 with search terms "delay in labour," "augmentation," "spontaneous vaginal birth," and "caesarean section." We found one Cochrane review.
Education into practice
• What ideas does this article offer you on how better to describe normal labour, particularly to nulliparous women?
• Are you aware of how prolonged labour is managed in your local maternity setting ? What is usual practice?
• How could you best describe the management options for women with prolonged labour?
How patients were involved in the creation of this article
The patient representative on our research group highlighted the lack of evidence on women's views on the experience of prolonged labour, which we have included. 
